Infections and treatment of patients with rheumatic diseases

Clinical and Experimental Rheumatology

Volumn 26, Issue 1 SUPPL. 48, 2008, Pages

  Atzeni, Fabiola ^a   Bendtzen, Klaus ^b   Bobbio Pallavicini, Francesca ^c   Conti, Fabrizio ^d   Cutolo, Maurizio ^e   Montecucco, Carlomaurizio ^c   Sulli, Alberto ^e   Valesini, Guido ^d   Sarzi Puttini, Piercarlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Rigshospitalet   (Denmark)

^c UNIVERSITY OF PAVIA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

Author keywords

Anti TNF agents; DMARDs; Gene technologies; Glucocorticoids; Vaccination

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLD SALT; HYDROCORTISONE; HYDROXYCHLOROQUINE; INFLIXIMAB; INFLUENZA VACCINE; ISONIAZID; LAMIVUDINE; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PLACEBO; PNEUMOCOCCUS VACCINE; PREDNISONE; RECOMBINANT BETA INTERFERON; RITUXIMAB; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIBODY PRODUCTION; AUTOIMMUNITY; CHRONIC INFLAMMATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; GENE TECHNOLOGY; HEPATITIS B; HIGH RISK PATIENT; HUMAN; HYDROCORTISONE RELEASE; IMMUNOGENICITY; INFECTION; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN FUNCTION; RECOMBINANT GENE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK REDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VACCINATION;

ANTIRHEUMATIC AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; INFECTION; RHEUMATIC DISEASES;

EID: 42549154807     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. MIKULS TR: Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003; 17: 729-52.
2. DORAN MF, CROWSON CS, POND GR, O'FALLON WM, GABRIEL SE: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-93.
3. LIONAKIS MS, KONTOYIANNIS DP: Glucocorticoids and invasive fungal infections. Lancet 2003; 362: 1828-38.
4. CUTOLO M, STRAUB RH, BIJLSMA JW: Neuroendocrine-immune interactions in synovitis. Nat Clin Pract Rheumatol 2007; 11: 627-34.
5. DALE DC, FAUCI AS, WOLFF SM: Alternate- day prednisone. Leukocyte kinetics and susceptibility to infections. N Engl J Med 1974; 291: 1154-8.
6. STRACHER AR, SOAVE R: Infectious complications of corticosteroid therapy. In LINN AN, PAGET SA (Eds.) Principles of Corticosteroid Therapy. London: Arnold, 2002: 419-30.
7. KLEIN NC, GO CH, CUNHA BA: Infections associated with steroid use. Infect Dis Clin North Am 2001; 15: 423-32.
8. STUCK AE, MINDER CE, FREY FJ: Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989; 11: 954-63.
9. VAN EVERDINGEN AA, JACOBS JW, SIEWERTSZ VAN REESEMA DR, BIJLSMA JW: Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, disease-modifying properties, and side effects: A randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002; 136: 1-12.
10. FRANKLIN J, LUNT M, BUNN D, SYMMONS D, SILMAN A: Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007; 66: 308-12.
11. DA SILVA JA, JACOBS JW, KIRWAN JR et al.: Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data. Ann Rheum Dis 2006; 65: 285-93.
12. HOES JN, JACOBS JW, BOERS M et al.: EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66: 1560-7.
13. BRASSAD P, KEZOUH A, SUISSA S: Antirheumatic drugs and the risk of tuberculosis. Clin Inf Dis 2006; 43: 717-22.
14. VAN DER VEEN MJ, VAN DER HEIDE A, KRUIZE AA, BIJLSMA JW: Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 1994; 53: 224-8.
15. WOLFE F, MICHAUD K, CHAKRAVARTY EF: Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology 2006; 45: 1370-5.
16. JENKS KA, STAMP LK, O'DONNELL JL, SAVAGE R, CHAPMAN P: Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol 2007; 34: 2201-3.
17. WOLFE F, CAPLAN L, MICHAUD K: Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia. Arthritis Rheum 2006; 54: 628-34.
18. MARRA CA, ESDAILE JM, GUHN D, FISHER JH, CHALMERS A, ANIS AH: The effectiveness and toxicity of cyclosporine A in rheumatoid arthritis: longitudinal analysis of a population-based registry. Arthritis Care Res 2001; 45: 240-5.
19. BENDIX G, BJELLE A: A 10-year follow up of parenteral gold therapy in patients with rheumatoid arthritis. Ann Rheum Dis 1996; 55: 169-76.
20. PIERINGER H, STUBBY U, BIESENBACH G: Patients with rheumatoid arthritis undergoing surgery: How should we deal with antirheumatic treatment? Semin Arthritis Rheum 2007, 36: 278-86.
21. DESAI SB, FURST, DE: Problems enountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 2006;20:757-90.
22. WALLIS RS, BRODER MS, WONG JY, HANSON ME, BEENHOUWER DO: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clini Infect Dis 2004; 38: 1261-5.
23. BOULMAN N, ROZENBAUM M, SLOBODIN G, ROSNER I: Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 723.
24. MANADAN AM, JOYCE K, SEQUEIRA W, BLOCK JA: Etanercept therapy in patients with a positive tuberculin skin test. Clin Exp Rheumatol 2007; 25: 743-5.
25. DORE RK, MATHEWS S, SCHECHTMAN J et al.:THe immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 40-6.
26. CALABRESE LH, ZEIN N, VASSILOPOULOS D: Safety of anti-tumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004; 63: 18-24.
27. SALLIOT C, GOSSEC L, RUYSSEN-WITRAND A et al.: Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: A systematic retrospective study of 707 patients. Arthritis Rheum 2005; 52: (Abstract) S340.
28. KROESEN S, WIDMER AF, TYNDALL A, HASLER P: Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003; 42: 617-21.
29. BONGARTZ T, SUTTON AJ, SWEETING MJ, BUCHAN I, MATTESON EL, MONTORI V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85.
30. DIXON WG, WATSON K, LUNT M, HYRICH KL, SILMAN AJ, SYMMONS DP: British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
31. ASKLING J, FORED, CM, GEBOREK P et al.: Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006; 65: 707-12.
32. LISTING J, STRANGFELD A, KARY S et al.: Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12.
33. SCHNEEWEISS S, SETOGUCHI S, WFINBLATT ME et al.: Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 1754-64.
34. BENDTZEN K: Anti-IFN BAb and NAb antibodies: A mini review. Neurology 2003; 61 (Suppl. 5): S6-S10.
35. BENDTZEN K, SVENSON M: Cytokine autoantibodies. In SHOENFELD Y, MERONI PL, GERSHWIN ME (Eds). Autoantibodies. Elsevier Press 2007. 299-307.
36. ROSS C, CLEMMESEN KM, SVENSON M et al.: Immunogenicity of interferon-b in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol 2000; 48: 706-12.
37. ROSS C, SVENSON M, CLEMMESEN KM, SORENSEN PS, KOCH-HENRIKSEN N, BENDTZEN K: Measuring and evaluating interferon-beta-induced antibodies in patients with multiple sclerosis. Mult Scler 2006; 12: 39-46.
38. SORENSEN PS, ROSS C, CLEMMESEN KM et al.: Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184-91.
39. BENDTZEN K, HANSEN MB, ROSS C, SVENSON M: Detection of autoantibodies to cytokines. Mol Biotechnol 2000; 14: 251-61.
40. BENDTZEN K, GEBOREK P, SVENSON M, LARSSON L, KAPETANOVIC MC, SAXNE T: Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor Infliximab. Arthritis Rheum 2006; 54: 3782-9.
41. AINSWORTH MA, BENDTZEN K, BRYNSKOV J: Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2007; Nov 19 [Epub ahead of print].
42. VAN VOLLENHOVEN RF, GUDBRANDSDOTTIR S, JONSDOTTIR T et al.: Correlation between etanercept-related TNF binding capacity in serum and clinical response to treatment in RA patients. American College of Rheumatology (ACR) Annual meeting, Presentation 272, poster 272, 2005.
43. SVENSON M, GEBOREK P, SAXNE T, BENDTZEN K: Monitoring patients treated with anti-TNF-alpha biopharmaceuticals - assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 2007; 46: 1828-34.
44. BOUZA E, MOYA JG, MUÑOZ P: Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am 2001; 15: 335-61.
45. SHOENFELD Y, ARON-MAOR A: Vaccination as an additional player in the mosaic autoimmunity. J Autoimmun 2000; 14: 1-10.
46. CONTI F, REZAI S, VALESINI G: Iaccination and rheumatic diseases: is there still a dilemma? Curr Rheumatol Review 2007; 13: 79-91.
47. DORAN MF, CROWSON CS, POND GR, O'FALLON WM, GABRIEL SE: Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-93.
48. VAN ALBADA-KUIPERS GA, LINTHORST J, PEETERS EA et al.: Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism. Arthritis Rheum 1988; 31: 667-71.
49. KAINE JL, KIVITZ AJ, BIRBARA C, LUO AY: Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007; 34: 272-9.
50. OREN S, MANDELBOIM M, BRAUN-MOSCOVICI Y et al.: Vaccination against influenza in rheumatoid arthritis - patients: The effect of rituximab on the humoral response. Ann Rheum Dis 2007 Dee 4 (Epub ahead of print).
51. VISVANATHAN S, KEENAN GF, BAKER DG, LEVINSON AI, WAGNER CL: Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007; 34: 952-7.